PLAU and apparent mineralocorticoid excess: Urokinase or urokinase-type plasminogen activator (uPA), a serine protease, is the most widely used drug for treating APE, which act as a catalyst for conversion of plasminogen to plasmin to resolve blood clots (Sasahara et al., 1967; Cheng et al., 2002).